Managing Chronic Neuropathic Pain: Recent Advances and New Challenges.

The randomized, double-blind, placebo-controlled two phase 1 studies conducted in 2017 concluded that although AV-101 did not reach statistical significance in reducing pain, there were consistent reductions for allodynia pain and mechanical and heat hyperalgesia.

also in 111,027 other papers